| Previous Close | 0.7734 |
| Open | 0.7798 |
| Bid | 0.7766 x 1500000 |
| Ask | 0.8230 x 1500000 |
| Day's Range | 0.7798 - 0.7798 |
| 52 Week Range | 0.7734 - 1.2535 |
| Volume | |
| Avg. Volume | 778 |
| Market Cap | 9.65B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | 11.14 |
| EPS (TTM) | 0.0700 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.03 (3.37%) |
| Ex-Dividend Date | Jun 05, 2023 |
| 1y Target Est | N/A |
China has approved its first domestically developed mRNA vaccine against COVID-19, CSPC Pharmaceutical Group Ltd said on Wednesday, a major achievement in a country that has declined to use Western COVID shots to support domestic research. China, whose home-grown vaccines are seen as less effective than the Moderna and Pfizer-BioNTech mRNA shots, has been racing to develop vaccines using messenger RNA (mRNA) technology since early 2020. The long-awaited approval comes as infections have fallen sharply across China since it suddenly dropped its strict "zero-COVID" curbs in December, making the sales outlook for the newly approved vaccine moderate.
China's CSPC Pharmaceutical Group Limited said on Wednesday its messenger RNA (mRNA) COVID-19 vaccine has received emergency use authorisation from Chinese health authorities. The approval from the National Medical Products Administration means CSPC is the first company cleared to provide an mRNA vaccine in China - but it comes as COVID cases decline across the country after a recent surge.